Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | Respiratory Research

Fig. 6

From: Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis

Fig. 6

 H&E images (left column) showing exact sections (black boxes) that were double stained against PD-1 and CD4. PD-1 and CD4 positivity is demarcated with green and red respectively, while DAPI which was used to stain the nuclei is demarcated with blue. Double stain images indicated higher PD-1 and CD4 expression upon bleomycin administration. Right column shows 2X zoomed images. White arrows are pointing representative double positive cells. (error bars: 50 μm) (Panel A). Quantification analysis showed that bleomycin treated mice presented with higher PD-1 compared to saline treated mice (p = 0.04), while mice treated with bleomycin and low dose pembrolizumab presented with lower PD-1 compared to mice treated with bleomycin only (p = 0.03, Kruskal-Wallis test) (Panel B). Pearson’s Rr quantification measurement of the colocalization of PD-1 and CD4. Treatment with pembrolizumab and/or bleomycin did not result to a significant change in the percentage of PD-1/CD4 colocalization (Panel C). Median PD-1 mRNA expression was significantly higher in lung tissues isolated from mice treated with bleomycin compared to littermates treated with saline at day 14 (Kruskal–Wallis test; saline vs. bleomycin: p = 0.008). Pembrolizumab treatment did not lead to statistically significant change in PD-1 mRNA expression (Panel D)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us